Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Alphabet

PayPal

Alphabet is a leader in two technologies that could transform the future. PayPal is a dirt cheap fintech leader with a stronger business than you might think.

The Best Stocks to Invest $5,000 in Right Now

UiPath

Science Applications International

Uncovering the illusive secrets with stocks to double your money is an endeavor that captures the imagination of many. But the quest for lucrative opportunities becomes increasingly challenging with the constant noise.

3 Secret Stocks to Double Your Money by 2028

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in two upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 10:30 a.m. ET. Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 4:00 p.m.

Vertex to Participate in Upcoming Investor Conferences

Vertex brought in more than $9.8 billion last year thanks to its flagship cystic fibrosis drugs. The company is moving closer to the finish line with a new cystic fibrosis treatment that may even beat its biggest blockbuster.

Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market

Ardelyx

VistaGen Therapeutics

Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to $3.08 trillion by 2030, with a compound annual growth rate of 14%.

3 Revolutionary Biotech Stocks Poised for 10X Surge

AbbVie

Eli Lilly

AbbVie is finding ways to grow despite losing patent exclusivity for its blockbuster, Humira. Eli Lilly has delivered impressive growth over the last 12 months, and more could be on the way.

3 Magnificent Growth Stocks to Buy Right Now

Vertex plans on submitting its pain candidate to regulators by mid-year. A young biotech company just announced it's working on a very similar pain candidate.

Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?

Regeneron Pharmaceuticals

Companies combating life-altering diseases can be compelling long-term investments. Vertex just won an approval that could supercharge its growth in the next few years.

2 Top Growth Stocks to Buy With $1,000 Right Now

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products.

Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.

Intuitive Surgical

Surgical robotics and the rare disease drug market are two rapidly growing areas of healthcare. Intuitive Surgical makes most of its money from recurring revenue, a business model that has held up.

2 Healthcare Growth Stocks That Are No-Brainer Buys Right Now

Airbnb

Netflix

Vertex Pharmaceuticals is in the middle of an extremely formative period for its business. Netflix is seeing a windfall of growth from its ad-supported tier, and profits are flowing.

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade.

bluebird bio

CRISPR Therapeutics

GoodRx Holdings

Gilead Sciences

Sarepta Therapeutics

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.

Gene therapy: Why does it cost millions for a single treatment?

Vertex's P/S ratio is very high, relative to most other biopharma stocks. It's important, though, to look to the future rather than the past when considering the company's valuation.

Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?

Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.

Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

Vertex Pharmaceuticals' shares have climbed nearly 80% in two years. Its share price recently reached an all-time high, and key catalysts ahead could push it higher.

Stock-Split Watch: Is Vertex Pharmaceuticals Next?

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT), for whom hematopoi.

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Healthcare spending represents a tremendous, multitrillion-dollar market opportunity. Vertex just earned another product approval, and more growth could be just over the horizon.

2 Healthcare Stocks That Could Help Set You Up for Life

Abbott Labs

The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains

QUALCOMM

SoFi Technologies

While many S&P 500 stocks are reaching recent highs, Wall Street analysts are also reassessing their price targets and issuing outlook changes and downgrades for a number of companies. Today, we introduce three stocks with price target cuts.

Cooling Off? 3 Popular Stocks With Recent Target Cuts

Drugmaker and cystic fibrosis specialist Vertex expects modest growth for 2024. The company has promising products in its pipeline, but they could still be years away.

Is Vertex Pharmaceuticals Stock a Buy Now?

DexCom

Its essential nature helps the healthcare industry generate more consistent consumer spending. DexCom is raking in profits from its latest product, and it's still looking at a vast long-term opportunity.

2 No-Brainer Healthcare Stocks to Buy Right Now

Novo Nordisk

Eli Lilly has major catalysts ahead. Novo Nordisk delivered strong growth in 2023 and could top that performance in 2024.

3 Stocks That Could Trounce the Market in 2024

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment and now is expanding into other areas that could bring in billion-dollar revenue. The company expects to file for the regulatory review of two potential blockbusters by midyear.

Could Vertex Pharmaceuticals Reach $500 in 2024?

Clearpoint Neuro Inc

Healthcare stocks are one of the best sectors to capture long-term innovation and sector strength. After all, healthcare needs are perennial, especially as the global population lives longer and can generally afford more than the bare minimum of care.

3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List

Vertex Pharmaceuticals is attempting to diversify its portfolio. Its candidate for treating acute pain will likely be successful if approved.

News for Vertex Pharmaceuticals Stock (VRTX)